Please wait while the formulary information is being retrieved.
DRUG IMAGES
PROGESTERONE 200 MG CAPSULE
PROGESTERONE 100 MG CAPSULE
The following indications for PROGESTERONE (progesterone) have been approved by the FDA:
Indications:
Abnormal uterine bleeding due to hormonal imbalance
Amenorrhea secondary to ovarian dysfunction
Endometrial hyperplasia prevention
Secondary amenorrhea
Professional Synonyms:
Abnormal uterine bleeding secondary to hormone imbalance
Endometrial hyperplasia prophylaxis
Secondary physiologic amenorrhea
Indications:
Abnormal uterine bleeding due to hormonal imbalance
Amenorrhea secondary to ovarian dysfunction
Endometrial hyperplasia prevention
Secondary amenorrhea
Professional Synonyms:
Abnormal uterine bleeding secondary to hormone imbalance
Endometrial hyperplasia prophylaxis
Secondary physiologic amenorrhea
The following dosing information is available for PROGESTERONE (progesterone):
No enhanced Dosing information available for this drug.
Progesterone is administered by orally, intravaginally, and by IM injection. Progesterone capsules are administered orally once daily at bedtime. Women who have difficulty swallowing the capsules should be advised to swallow progesterone capsules while in an upright position and with adequate amounts of fluid (e.g., a glass of water).
Administration at bedtime may alleviate some of the adverse effects (e.g., dizziness, blurred vision) associated with the drug. Progesterone vaginal gel should not be administered concurrently with other intravaginal preparations. If therapy with another agent administered intravaginally is needed, such therapy should be administered 6 hours before or 6 hours after progesterone vaginal gel.
Concomitant use of progesterone vaginal inserts with other preparations that are administered intravaginally is not recommended. Although specific studies have not been undertaken, the possibility exists that concomitant administration of a progesterone vaginal insert with another preparation administered intravaginally may alter the release and absorption of progesterone from the vaginal insert.
Administration at bedtime may alleviate some of the adverse effects (e.g., dizziness, blurred vision) associated with the drug. Progesterone vaginal gel should not be administered concurrently with other intravaginal preparations. If therapy with another agent administered intravaginally is needed, such therapy should be administered 6 hours before or 6 hours after progesterone vaginal gel.
Concomitant use of progesterone vaginal inserts with other preparations that are administered intravaginally is not recommended. Although specific studies have not been undertaken, the possibility exists that concomitant administration of a progesterone vaginal insert with another preparation administered intravaginally may alter the release and absorption of progesterone from the vaginal insert.
| DRUG LABEL | DOSING TYPE | DOSING INSTRUCTIONS |
|---|---|---|
| PROGESTERONE 100 MG CAPSULE | Maintenance | Adults take 2 capsules (200 mg) by oral route once daily in the evening for 12 days sequentially per 28 day cycle |
| PROGESTERONE 200 MG CAPSULE | Maintenance | Adults take 1 capsule (200 mg) by oral route once daily in the evening for 12 days sequentially per 28 day cycle |
| PROGESTERONE 500 MG/10 ML VIAL | Maintenance | Adults inject 0.1 milliliter (5 mg) by intramuscular route once daily |
| DRUG LABEL | DOSING TYPE | DOSING INSTRUCTIONS |
|---|---|---|
| PROGESTERONE 500 MG/10 ML VIAL | Maintenance | Adults inject 0.1 milliliter (5 mg) by intramuscular route once daily |
| PROGESTERONE 100 MG CAPSULE | Maintenance | Adults take 2 capsules (200 mg) by oral route once daily in the evening for 12 days sequentially per 28 day cycle |
| PROGESTERONE 200 MG CAPSULE | Maintenance | Adults take 1 capsule (200 mg) by oral route once daily in the evening for 12 days sequentially per 28 day cycle |
The following drug interaction information is available for PROGESTERONE (progesterone):
There are 0 contraindications.
There are 1 severe interactions.
These drug interactions can produce serious consequences in most patients. Actions required for severe interactions include, but are not limited to, discontinuing one or both agents, adjusting dosage, altering administration scheduling, and providing additional patient monitoring. Review the full interaction monograph for more information.
| Drug Interaction | Drug Names |
|---|---|
| Progestin Replacement Therapy/Ulipristal SEVERITY LEVEL: 2-Severe Interaction: Action is required to reduce the risk of severe adverse interaction. MECHANISM OF ACTION: Ulipristal is a progesterone receptor modulator and binds to the progesterone receptor with high affinity.(1)(2) CLINICAL EFFECTS: Concurrent use of ulipristal may make progesterone products ineffective.(1,2) These agents may also make ulipristal ineffective.(3) PREDISPOSING FACTORS: None determined. PATIENT MANAGEMENT: Products containing progestin should not be used within 12 days of ulipristal discontinuation.(3) DISCUSSION: Ulipristal is a progesterone receptor modulator and binds to the progesterone receptor with high affinity, thus it may interfere with the efficacy of progestin products.(1-3) These products may also make ulipristal ineffective.(3) |
ELLA |
There are 0 moderate interactions.
The following contraindication information is available for PROGESTERONE (progesterone):
Drug contraindication overview.
No enhanced Contraindications information available for this drug.
No enhanced Contraindications information available for this drug.
There are 3 contraindications.
Absolute contraindication.
| Contraindication List |
|---|
| Carcinoma of breast |
| Neoplasm of liver |
| Porphyria |
There are 14 severe contraindications.
Adequate patient monitoring is recommended for safer drug use.
| Severe List |
|---|
| Acute myocardial infarction |
| Bed-ridden |
| Cerebrovascular accident |
| Coronary artery disease |
| Deep venous thrombosis |
| Disease of liver |
| Migraine |
| Obesity |
| Predisposition to thrombosis |
| Pulmonary thromboembolism |
| Retinal thrombosis |
| Thromboembolic disorder |
| Thrombophlebitis |
| Tobacco smoker |
There are 5 moderate contraindications.
Clinically significant contraindication, where the condition can be managed or treated before the drug may be given safely.
| Moderate List |
|---|
| Depression |
| Diabetes mellitus |
| Edema |
| Hyperlipidemia |
| Hypertension |
The following adverse reaction information is available for PROGESTERONE (progesterone):
Adverse reaction overview.
No enhanced Common Adverse Effects information available for this drug.
No enhanced Common Adverse Effects information available for this drug.
There are 37 severe adverse reactions.
| More Frequent | Less Frequent |
|---|---|
|
Abdominal distension Abnormal vaginal bleeding Irregular menstrual periods |
Endometrial hyperplasia Hypersensitivity drug reaction Mood changes |
| Rare/Very Rare |
|---|
|
Abnormal hepatic function tests Acute myocardial infarction Anaphylaxis Angioedema Cerebrovascular accident Depression Ectopic pregnancy Eosinophilic pneumonia Erythema multiforme Erythema nodosum Galactorrhea not associated with childbirth Gallbladder obstruction Hepatitis Hypersensitivity drug reaction Hypertension Idiopathic intracranial hypertension Jaundice Malignant neoplasm of the ovary Menorrhagia Migration of implant Obstructive hyperbilirubinemia Optic neuritis Ovarian cyst Pancreatitis Pruritus of skin Pulmonary thromboembolism Retinal thrombosis Skin rash Thromboembolic disorder Thrombophlebitis Thrombotic disorder |
There are 77 less severe adverse reactions.
| More Frequent | Less Frequent |
|---|---|
|
Acute abdominal pain Appetite changes Back pain Edema Fatigue General weakness Headache disorder Injection site sequelae Mastalgia Myalgia Vaginitis Weight gain Weight loss |
Acne vulgaris Amenorrhea Back pain Cervical discharge Diarrhea Dizziness Drowsy Dysmenorrhea Dyspepsia Ectropion of cervix Flu-like symptoms Hypertonia Implant site reaction Menstrual disorder Nausea Palpitations Pharyngitis Pruritus of skin Vaginal discharge |
| Rare/Very Rare |
|---|
|
Acne vulgaris Alopecia Amenorrhea Body fluid retention Cervical discharge Chest discomfort Chloasma Constipation Cystitis Drowsy Dysuria Ectropion of cervix Fatigue Fever Fibrocystic breast disease Flatulence Flushing Galactorrhea not associated with childbirth Genital organ pruritus Gynecomastia Hirsutism Hyperglycemia Insomnia Irritability Libido changes Mastalgia Migraine Musculoskeletal pain Myalgia Nausea Nervousness Pain Pain in extremities Paresthesia Rhinitis Seborrhea Sinusitis Skin rash Symptoms of anxiety Urinary incontinence Urinary tract infection Urticaria Visual changes Vomiting Weight gain |
The following precautions are available for PROGESTERONE (progesterone):
No enhanced Pediatric Use information available for this drug.
Contraindicated
Severe Precaution
Management or Monitoring Precaution
Contraindicated
| None |
Severe Precaution
| None |
Management or Monitoring Precaution
| None |
Progesterone is used to support embryo implantation and maintain pregnancy as a component of assisted reproductive technology (ART) treatment in infertile women. Such use is associated with increased ongoing pregnancy rates. Although progestins have been used beginning in the first trimester of pregnancy to prevent habitual abortion or to treat threatened abortion, there is no adequate evidence from well-controlled studies to substantiate the efficacy of progestins for these uses; however, there is evidence of potential adverse effects on the fetus when these drugs are administered during the first 4 months of pregnancy.
In addition, in most women, the cause of abortion is a defective ovum, which progestins could not be expected to influence. Because of their uterine-relaxant effects, progestins may delay spontaneous abortion of fertilized defective ova. Masculinization of the female fetus has reportedly occurred when progestins were used during pregnancy.
Clitoral hypertrophy has been reported in a few female neonates born to women who had received medroxyprogesterone during pregnancy. An association between intrauterine exposure to female sex hormones and congenital anomalies, including cardiovascular and limb defects, has been suggested. (See Cautions: Pregnancy, Fertility, and Lactation, in Estrogen-Progestin Combinations 68:12.) Use of progestins generally is not recommended during the first 4 months of pregnancy. Progesterone should not be used to induce withdrawal bleeding as a test for pregnancy.
In addition, in most women, the cause of abortion is a defective ovum, which progestins could not be expected to influence. Because of their uterine-relaxant effects, progestins may delay spontaneous abortion of fertilized defective ova. Masculinization of the female fetus has reportedly occurred when progestins were used during pregnancy.
Clitoral hypertrophy has been reported in a few female neonates born to women who had received medroxyprogesterone during pregnancy. An association between intrauterine exposure to female sex hormones and congenital anomalies, including cardiovascular and limb defects, has been suggested. (See Cautions: Pregnancy, Fertility, and Lactation, in Estrogen-Progestin Combinations 68:12.) Use of progestins generally is not recommended during the first 4 months of pregnancy. Progesterone should not be used to induce withdrawal bleeding as a test for pregnancy.
Progestins are reportedly distributed into milk. The manufacturers warn that the possible effects of progestins in milk on nursing infants have not been determined.
No enhanced Geriatric Use information available for this drug.
The following prioritized warning is available for PROGESTERONE (progesterone):
WARNING: Progesterone is sometimes used with another medication (a type of estrogen) as combination hormone replacement therapy (HRT) in women after menopause. Combination HRT may rarely cause very serious (possibly fatal) problems from blood clots (such as heart attack, stroke, blood clots in the lungs or legs), dementia, and breast cancer. Some of these risks appear to depend on the length of treatment and other factors.
Combination HRT should be used for the shortest possible length of time at the lowest effective dose so you can obtain the benefits and minimize the chance of serious side effects from long-term treatment. Combination HRT should not be used to prevent heart disease or dementia. Discuss the risks and benefits of treatment and your personal health history with your doctor.
If you take combination HRT, check with your doctor regularly (such as every 3-6 months) to see if you still need to take it. If you use this medication for an extended period, you should have a complete physical exam at regular intervals (such as once a year) or as directed by your doctor. See also Notes section.
WARNING: Progesterone is sometimes used with another medication (a type of estrogen) as combination hormone replacement therapy (HRT) in women after menopause. Combination HRT may rarely cause very serious (possibly fatal) problems from blood clots (such as heart attack, stroke, blood clots in the lungs or legs), dementia, and breast cancer. Some of these risks appear to depend on the length of treatment and other factors.
Combination HRT should be used for the shortest possible length of time at the lowest effective dose so you can obtain the benefits and minimize the chance of serious side effects from long-term treatment. Combination HRT should not be used to prevent heart disease or dementia. Discuss the risks and benefits of treatment and your personal health history with your doctor.
If you take combination HRT, check with your doctor regularly (such as every 3-6 months) to see if you still need to take it. If you use this medication for an extended period, you should have a complete physical exam at regular intervals (such as once a year) or as directed by your doctor. See also Notes section.
The following icd codes are available for PROGESTERONE (progesterone)'s list of indications:
| Abnormal uterine bleeding due to hormonal imbalance | |
| N92.4 | Excessive bleeding in the premenopausal period |
| N92.5 | Other specified irregular menstruation |
| N92.6 | Irregular menstruation, unspecified |
| N93.8 | Other specified abnormal uterine and vaginal bleeding |
| N93.9 | Abnormal uterine and vaginal bleeding, unspecified |
| N95.0 | Postmenopausal bleeding |
| Amenorrhea secondary to ovarian dysfunction | |
| E28.8 | Other ovarian dysfunction |
| E28.9 | Ovarian dysfunction, unspecified |
| N91.0 | Primary amenorrhea |
| N91.1 | Secondary amenorrhea |
| N91.2 | Amenorrhea, unspecified |
| Secondary amenorrhea | |
| N91.1 | Secondary amenorrhea |
| N91.2 | Amenorrhea, unspecified |
Formulary Reference Tool